Headlines about Aptevo Therapeutics (NASDAQ:APVO) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.4671558368204 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Aptevo Therapeutics (APVO) traded up 2.26% during mid-day trading on Wednesday, reaching $1.81. The company had a trading volume of 316,882 shares. Aptevo Therapeutics has a 52-week low of $1.70 and a 52-week high of $3.00. The firm’s 50-day moving average price is $1.82 and its 200 day moving average price is $1.94. The company’s market cap is $38.77 million.

Aptevo Therapeutics (NASDAQ:APVO) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.08. The firm had revenue of $10.76 million during the quarter. Aptevo Therapeutics had a negative return on equity of 64.80% and a negative net margin of 296.64%. Equities analysts expect that Aptevo Therapeutics will post ($2.26) EPS for the current year.

Separately, ValuEngine upgraded Aptevo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 6th.

TRADEMARK VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-aptevo-therapeutics-apvo-stock-price.html.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Insider Buying and Selling by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Stock Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related stocks with our FREE daily email newsletter.